Therapy Areas: Vaccines
Merck's CAPVAXIVE shows promising immune responses in adults at risk of pneumococcal disease
16 October 2024 - Biopharmaceutical company Merck (NYSE: MRK), also known as MSD outside the US and Canada, has announced positive results from the STRIDE-8 Phase 3 trial for CAPVAXIVE (Pneumococcal 2...
GSK PLC announces acceptance of NDA for gepotidacin by US FDA
16 October 2024 - Biopharmaceutical company GSK PLC (LSE: GSK) (NYSE: GSK) announced on Wednesday that the US Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for gepotid...
Sanofi in talks to sell Opella stake
11 October 2024 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Friday that it is in discussions with US private equity firm Clayton, Dubilier & Rice (CD&...
Orlance receives research grant to develop Enhanced Seasonal Influenza Vaccine
11 October 2024 - US biotech company Orlance Inc announced on Thursday that it has received a National Institutes of Health (NIH) Fast Track Small Business Innovation Research (SBIR) grant to produce ...
Novavax's updated 2024-2025 Nuvaxovid COVID-19 Vaccine receives European Commission Marketing Authorisation
10 October 2024 - US biotechnology company Novavax Inc (Nasdaq: NVAX) announced on Wednesday that it has received Marketing Authorisation from the European Commission for its updated 2024-2025 Nuvaxov...
Anixa Biosciences plans Phase 2 breast cancer vaccine study
25 September 2024 - California-based biotechnology company Anixa Biosciences Inc (NASDAQ: ANIX) announced on Tuesday its plan for a Phase 2 study of its breast cancer vaccine.The Phase 1 trial is bein...